Here is my review.

Summary
- The paper introduces TimeWarn, an interpretable two-level attention model that explicitly accounts for irregular measurement intervals in EHRs by learning a per-variable time decay that modulates both variable- and visit-level attention. 
- On MIMIC-IV and eICU, TimeWarn achieves modest but consistent gains over strong baselines (GRU-D and RETAIN) for predicting sepsis 6 hours before onset, with additional ablations and a brief attention analysis.

Strengths
- Clear motivation for handling irregular sampling and for interpretability in clinical decision support.
- Simple, plausible mechanism: learned exponential decay applied to attention at two levels; compatible with RETAIN-style interpretability.
- Empirical results on two large public ICU datasets with multiple seeds; consistent improvements in AUROC and AUPRC over strong time-aware and interpretable baselines.
- Basic ablation demonstrates that time decay is contributing meaningfully.
- Attention analysis highlights clinically meaningful variables (lactate, RR, MAP), aligning with expectations.

Weaknesses and concerns
- Novelty is incremental: combining RETAIN-style attention with a GRU-D-like decay is a natural extension; related work on time-aware attention and continuous-time models is under-cited and not compared (e.g., time-aware self-attention/transformers, T-LSTM variants, ODE-RNN/Latent ODE with attention, RAIM/Hi-BEHRT style models).
- Methodological details are underspecified:
  - Is decay per variable with its own parameters (w, b) or shared? Are parameters constrained (e.g., nonnegative w) to ensure monotone decay?
  - Are attention weights re-normalized after multiplying by the decay factors? If not, how does that affect interpretability and stability?
  - Construction of window embeddings from values and missingness masks lacks detail (imputation, normalization, handling multiple measurements within a window, categorical handling).
  - Exact variable list (the 32 features), preprocessing choices (winsorization, unit harmonization), and label derivation specifics are not fully described.
- Fairness of comparisons: baselines reportedly use hyperparameters from original papers, while TimeWarn is tuned via grid search; this can bias results. At minimum, tune GRU-D and RETAIN comparably or provide a sensitivity analysis.
- Statistical testing is absent; given the modest improvements (e.g., +0.016 AUROC), significance tests or confidence intervals would strengthen claims.
- Limited ablation depth: only two ablations. Missing studies such as:
  - Per-variable vs shared decay parameters.
  - Effect of decay on only visit- vs only variable-level attention with re-normalization variants.
  - Fixed vs learned half-lives.
  - Sensitivity to window size and to inclusion/exclusion of recent vs stale measurements.
- Interpretability claims rely on average attention weights; the “attention as explanation” debate is not addressed. No case studies, counterfactual checks, or faithfulness probes.
- External validity and label leakage: unclear whether medication/vasopressor orders, cultures, or antibiotics are among the 32 variables; if included, they can leak label timing. Clarify and, if needed, conduct leakage checks.

Questions for authors
- Do you re-normalize attentions after applying time decay? If yes, how? If no, how do you interpret the resulting weights?
- Are decay parameters per variable? Are they constrained to enforce monotone decay? What are learned half-lives for key variables?
- What exact 32 variables are used, and how are multiple measurements per hour aggregated?
- Did you tune GRU-D and RETAIN on your validation sets? If not, can you provide tuned baselines?
- Any significance testing of the improvements? Provide CIs or p-values.
- Are antibiotics/vasopressors/cultures included as predictors? How did you mitigate potential label leakage?

Overall assessment
- This is a well-motivated, clearly written, and practically useful incremental contribution. The proposed mechanism is simple and effective, with consistent gains on two datasets and preserved interpretability. However, novelty is limited, and important methodological and experimental details are missing, with some concerns about fairness of comparisons and depth of analysis. With additional clarifications, tuned baselines, and stronger ablations, the paper would be substantially stronger.

Scores (0–100)
- Soundness: 75
- Novelty: 65
- Significance: 70
- Clarity: 78

Final average score: 72.0

Recommendation: Accept (borderline). The contribution is incremental but useful, empirically validated across two datasets, and relevant to clinical ML practice. Strengthening methodological detail, fairness of comparisons, and interpretability/ablations in the camera-ready is recommended.